

CORRECTION

Open Access



Correction to: Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis

Anja Gäckler^{1*}, Ulf Schönermarck², Vladimir Dobronravov³, Gaetano La Manna⁴, Andrew Denker⁵, Peng Liu⁵, Maria Vinogradova⁶, Sung-Soo Yoon⁷ and Manuel Praga⁸

Correction to: BMC Nephrol (2021) 22:5
<https://doi.org/10.1186/s12882-020-02190-0>

Following publication of the original article [1], authors informed us that the PLS file was to be included in the supplementary information.

The original article [1] has been corrected.

Author details

¹Department of Nephrology, University Hospital Essen, University Duisburg-Essen, Essen, Germany. ²Medizinische Klinik IV, LMU Klinikum, LMU, Munich, Germany. ³Pavlov University, Research Institute of Nephrology, St. Petersburg, Russia. ⁴Department of Experimental Diagnostic and Specialty Medicine (DIMES), Nephrology, Dialysis and Renal Transplant Unit, St. Orsola Hospital, University of Bologna, Bologna, Italy. ⁵Alexion Pharmaceuticals, Inc., Boston, USA. ⁶National Medical Research Centre for Obstetrics and Gynecology, Moscow, Russia. ⁷Seoul National University Hospital, Seoul, Republic of Korea. ⁸Instituto de Investigación Hospital Universitario 12 de Octubre i+12, Madrid, Spain.

Published online: 02 February 2021

Reference

1. Gäckler A, et al. Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis. *BMC Nephrol.* 2021;22:5 <https://doi.org/10.1186/s12882-020-02190-0>.

The original article can be found online at <https://doi.org/10.1186/s12882-020-02190-0>.

* Correspondence: Anja.Gaekler@uk-essen.de

¹Department of Nephrology, University Hospital Essen, University Duisburg-Essen, Essen, Germany

Full list of author information is available at the end of the article



© The Author(s). 2021 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.